AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19221352 — intervention group
Group type: COMPARATOR
Intervention: Insulin analogues
Number of subjects: 117
Study 17319816 — intervention group
Group type: EXPERIMENTAL
Intervention: Retransfusion system (Bellovac, AstraTech AB)
Number of subjects: 160
Study 17319816 — intervention group
Group type: COMPARATOR
Intervention: Regular drain (Abdovac, AstraTech AB)
Number of subjects: 160
Study 17319816 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Number of subjects: 160
Study 17319816 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 160
Study 15378838 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of plutonium
Number of subjects: 0
Study 15378838 — intervention group
Group type: COMPARATOR
Intervention: High doses of gamma rays
Number of subjects: 0
Study 15378838 — intervention group
Group type: EXPERIMENTAL
Intervention: High plutonium and high gamma-ray groups
Number of subjects: 0
Study 12600112 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (3 x 10^6 added to the priming solution of ECC)
Number of subjects: 24
Study 12600112 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone combined with aprotinin (3 x 10^6 aprotinin + bolus of 1 mg/kg amrinone followed by 8 micrograms/(kg.min) maintenance infusion)
Number of subjects: 24
Study 12600112 — intervention group
Group type: COMPARATOR
Intervention: Control group (equivalent prime volume without aprotinin)
Number of subjects: 24
Study 9379354 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg)
Number of subjects: 0
Study 1586821 — intervention group
Group type: EXPERIMENTAL
Intervention: Home physiotherapy
Number of subjects: 124
Study 1586821 — intervention group
Group type: COMPARATOR
Intervention: Day hospital attendance
Number of subjects: 124
Study 3099486 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 5 mg (30 mg/day)
Number of subjects: 15
Study 3099486 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 20 mg (120 mg/day)
Number of subjects: 15
Study 3099486 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 40 mg (240 mg/day)
Number of subjects: 15
Study 3099486 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 80 mg (480 mg/day)
Number of subjects: 15
Study 3099486 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of ISDN 80 mg (480 mg/day) for 4 weeks
Number of subjects: 15
Study 3099486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 2.6 mg (single dose)
Number of subjects: 15
Study 3099486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 6.5 mg
Number of subjects: 15
Study 3099486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 10 mg
Number of subjects: 15
Study 3099486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 20 mg
Number of subjects: 15
Study 3099486 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin 5 cm2 patch
Number of subjects: 15
Study 3099486 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin 10 cm2 patch
Number of subjects: 15
Study 3099486 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin 20 cm2 patch
Number of subjects: 15
Study 30372511 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived sleep quality (assessed using the Pittsburgh Sleep Quality Index - PSQI)
Number of subjects: 200
Study 30372511 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived sleep quality
Number of subjects: 200
Study 30372511 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression severity
Number of subjects: 200
Study 29458406 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyriproxyfen/spinosad combination treatment of permanent water storage containers
Number of subjects: 0
Study 29458406 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26746044 — intervention group
Group type: EXPERIMENTAL
Intervention: IV TXA
Number of subjects: 100
Study 25358424 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathlessness Intervention Service (BIS)
Number of subjects: 67
Study 25358424 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 67
Study 22664558 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced-education game (SE game) with 40 validated multiple-choice questions, sent 2 questions every 2 days (Cohort A)
Number of subjects: 1470
Study 22664558 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced-education game (SE game) with 40 validated multiple-choice questions, sent 4 questions every 4 days (Cohort B)
Number of subjects: 1470
Study 19879596 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 1.875 g/d
Number of subjects: 194
Study 19879596 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/d
Number of subjects: 194
Study 19879596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 16839823 — intervention group
Group type: EXPERIMENTAL
Intervention: telephone‐based, individualized motivationally‐tailored feedback
Number of subjects: 239
Study 16839823 — intervention group
Group type: EXPERIMENTAL
Intervention: print‐based, individualized motivationally‐tailored feedback
Number of subjects: 239
Study 16839823 — intervention group
Group type: COMPARATOR
Intervention: contact‐control delayed treatment group
Number of subjects: 239
Study 17012863 — intervention group
Group type: EXPERIMENTAL
Intervention: fowlpox + HIV genes
Number of subjects: 35
Study 17012863 — intervention group
Group type: EXPERIMENTAL
Intervention: fowl pox + HIV genes + interferon gamma
Number of subjects: 35
Study 17012863 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35
Study 12066113 — intervention group
Group type: COMPARATOR
Intervention: Paracervical block with no wait (group 1, n = 93)
Number of subjects: 199
Study 12066113 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block with 3-5 minute wait (group 2, n = 101)
Number of subjects: 199
Study 12066113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (used during the procedure)
Number of subjects: 199
Study 9461356 — intervention group
Group type: EXPERIMENTAL
Intervention: Spina bifida patients
Number of subjects: 148
Study 9461356 — intervention group
Group type: COMPARATOR
Intervention: Atopic children
Number of subjects: 148
Study 9461356 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 148
Study 9461356 — intervention group
Group type: EXPERIMENTAL
Intervention: Spina bifida patients with latex sensitization
Number of subjects: 148
Study 8534533 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 L of balanced electrolyte/polyethylene glycol solution (PEG)
Number of subjects: 216
Study 8534533 — intervention group
Group type: COMPARATOR
Intervention: Senna laxatives and sodium phosphate enemas
Number of subjects: 216
Study 2120087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cyst aspiration in group A
Number of subjects: 37
Study 2120087 — intervention group
Group type: COMPARATOR
Intervention: Non-aspirated ovarian cysts in group A
Number of subjects: 37
Study 2120087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cyst aspiration in group B
Number of subjects: 37
Study 2120087 — intervention group
Group type: COMPARATOR
Intervention: Non-aspirated ovarian cysts in group B
Number of subjects: 37
Study 7004480 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymoral (exact dosage and duration not specified)
Number of subjects: 102
Study 31908066 — intervention group
Group type: EXPERIMENTAL
Intervention: SR-dexamphetamine (2 x 30 mg/day)
Number of subjects: 73
Study 31908066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 30422953 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressant therapy
Number of subjects: 0
Study 30422953 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 29211123 — intervention group
Group type: EXPERIMENTAL
Intervention: Morse Taper (MT) implants
Number of subjects: 40
Study 29211123 — intervention group
Group type: COMPARATOR
Intervention: External Hexagon (EH) implants
Number of subjects: 40
Study 24936090 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice consisting of feedback on alcohol and health, written information, and an offer of an appointment with an Alcohol Health Worker
Number of subjects: 802
Study 24936090 — intervention group
Group type: COMPARATOR
Intervention: Control treatment consisting of a leaflet on health and lifestyle
Number of subjects: 802
Study 23376474 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-light walker (PLW) stimulus
Number of subjects: 24
Study 21545399 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxcinod 750 mg twice daily
Number of subjects: 131
Study 21545399 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily
Number of subjects: 131
Study 19057405 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at different frequencies (30, 35, 40, and 50 Hz), displacements (2-4 mm vs. 4-6 mm), and durations (30, 45, and 60 seconds)
Number of subjects: 20
Study 16950221 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 29
Study 16950221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 14756387 — intervention group
Group type: EXPERIMENTAL
Intervention: Regitine 40 mg tablet formulation
Number of subjects: 36
Study 14756387 — intervention group
Group type: COMPARATOR
Intervention: Vasomax 40 mg tablet formulation
Number of subjects: 36
Study 11442181 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Activities Questionnaire (VAQ)
Number of subjects: 607
Study 11442181 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms attributed to glaucoma
Number of subjects: 607
Study 11442181 — intervention group
Group type: EXPERIMENTAL
Intervention: Central and pericentral visual field measures
Number of subjects: 607
Study 11442181 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated binocular visual field scores
Number of subjects: 607
Study 9776327 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drug treatment (AEDs)
Number of subjects: 102
Study 9776327 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 102
Study 9776327 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-drug discontinuation assessment
Number of subjects: 102
Study 8112232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 98
Study 8112232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 3053457 — intervention group
Group type: COMPARATOR
Intervention: No specific infection prophylaxis in a conventional hospital room (control, 100 patients)
Number of subjects: 342
Study 3053457 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic systemic antibiotics (PSA) in a conventional hospital room (PSA group, 101 patients)
Number of subjects: 342
Study 3053457 — intervention group
Group type: EXPERIMENTAL
Intervention: Decontamination and isolation in a laminar air flow (LAF) room (LAF group, 65 patients)
Number of subjects: 342
Study 3053457 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA in an LAF room (LAF+PSA group, 76 patients)
Number of subjects: 342
Study 31702883 — intervention group
Group type: EXPERIMENTAL
Intervention: Difelikefalin (0.5 μg/kg)
Number of subjects: 378
Study 31702883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 30611123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients undergoing coronary angiography
Number of subjects: 480
Study 30611123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 480
Study 30611123 — intervention group
Group type: COMPARATOR
Intervention: Non-cancer patients (control)
Number of subjects: 480
Study 27397551 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy without antifungal prophylaxis
Number of subjects: 969
Study 25938241 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive-behavioral therapy (iCBT) for 9 weeks
Number of subjects: 76
Study 25938241 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 76
Study 24634923 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 144
Study 24634923 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 144
Study 20089204 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin supplements (folate 1 mg, vitamin B12 500 microg, vitamin B6 10 mg)
Number of subjects: 276
Study 20089204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 19127918 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm needle moxibustion
Number of subjects: 40
Study 19127918 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of tablet Caltrate with Vit D2
Number of subjects: 40
Study 16859470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal and anal EMLA cream (subgroup A)
Number of subjects: 98
Study 16859470 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound gel as placebo (subgroup B)
Number of subjects: 98
Study 14516238 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-driven treatment of posttraumatic stress
Number of subjects: 101
Study 14516238 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 101
Study 10918946 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost (CAS 88475‐69‐8)
Number of subjects: 0
Study 10918946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (CAS 73963‐72‐1)
Number of subjects: 0
Study 10918946 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8865639 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency modulation (FM) detection with modulation rates of 2, 5, 10, and 20 Hz for carrier frequencies up to 4 kHz.
Number of subjects: 0
Study 8865639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FM and amplitude modulation (AM) detection for a 1-kHz carrier with fm = 2 Hz.
Number of subjects: 0
Study 8865639 — intervention group
Group type: EXPERIMENTAL
Intervention: FM detection in quiet for carrier frequencies of 0.25, 1.0, and 6.0 kHz.
Number of subjects: 0
Study 1633720 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg hidrosmin, 1 capsule 3-times daily for 45 days
Number of subjects: 57
Study 1633720 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 1 capsule 3-times daily for 45 days
Number of subjects: 57
Study 6510452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release isosorbide dinitrate (ISDN) 40 mg
Number of subjects: 20
Study 6510452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31372762 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic profiling in patients with myasthenia gravis (MG)
Number of subjects: 46
Study 31372762 — intervention group
Group type: COMPARATOR
Intervention: Rheumatoid arthritis (RA)
Number of subjects: 46
Study 31372762 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 46
Study 28073949 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 0
Study 28073949 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct feedback (safety messaging)
Number of subjects: 0
Study 28073949 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives and direct feedback combined
Number of subjects: 0
Study 27473188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-micronized palmitoylethanolamide (um-PEA) 600 mg twice a day
Number of subjects: 0
Study 27473188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23512705 — intervention group
Group type: EXPERIMENTAL
Intervention: IBHB (300 mg, twice daily)
Number of subjects: 50
Study 23512705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23196811 — intervention group
Group type: EXPERIMENTAL
Intervention: Navilas laser system by experienced operator
Number of subjects: 2
Study 23196811 — intervention group
Group type: COMPARATOR
Intervention: Navilas laser system by inexperienced operator
Number of subjects: 2
Study 20637968 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed pellets from MS-sNT (60 mg morphine/2.4 mg naltrexone)
Number of subjects: 24
Study 20637968 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone solution (2.4 mg)
Number of subjects: 24
Study 20637968 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole MS-sNT capsule (60 mg morphine/2.4 mg naltrexone)
Number of subjects: 24
Study 20637968 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed MS-sNT
Number of subjects: 24
Study 20637968 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole MS-sNT
Number of subjects: 24
Study 20637968 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone solution
Number of subjects: 24
Study 17252564 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy intensification (Capizzi II)
Number of subjects: 0
Study 16226759 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg sublingual nitroglycerin
Number of subjects: 24
Study 16226759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12109416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 90
Study 12109416 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 90
Study 9925046 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-presentation condition (patients presented themselves as successful copers)
Number of subjects: 42
Study 9925046 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem disclosure condition (patients discussed problems with managing their illness)
Number of subjects: 42
Study 9925046 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients viewed a medical videotape about adjusting to dialysis)
Number of subjects: 42
Study 7485884 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 1078
Study 7485884 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 1078
Study 7485884 — intervention group
Group type: COMPARATOR
Intervention: Mini-lap cholecystectomy
Number of subjects: 1078
Study 2123603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardial friction rub present
Number of subjects: 810
Study 2123603 — intervention group
Group type: COMPARATOR
Intervention: No pericardial friction rub
Number of subjects: 810
Study 7325345 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl epidurally (0.1‐0.2 mg diluted with 0.9% saline solution)
Number of subjects: 20
Study 7325345 — intervention group
Group type: COMPARATOR
Intervention: Systemic opiate therapy by intramuscular application of piritramide (Dipidolor, 15‐25 mg)
Number of subjects: 20
Study 30628797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic psychotherapy with transference work interventions
Number of subjects: 100
Study 30628797 — intervention group
Group type: COMPARATOR
Intervention: Dynamic psychotherapy without transference work interventions
Number of subjects: 100
Study 28218555 — intervention group
Group type: EXPERIMENTAL
Intervention: Millard's technique combined with McComb's technique
Number of subjects: 359
Study 28218555 — intervention group
Group type: COMPARATOR
Intervention: Tennison‐Randall's technique
Number of subjects: 359
Study 28218555 — intervention group
Group type: COMPARATOR
Intervention: Center's own technique with nose plugs
Number of subjects: 359
Study 25070350 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 126
Study 25070350 — intervention group
Group type: COMPARATOR
Intervention: Losartan or Ramipril
Number of subjects: 126
Study 23514242 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Time Medication Monitoring system (RTMM) with tailored text-messages
Number of subjects: 220
Study 21291439 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents in treatment for depression
Number of subjects: 223
Study 21291439 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed parents (control group)
Number of subjects: 223
Study 21291439 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' level of depression
Number of subjects: 223
Study 21291439 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental acceptance
Number of subjects: 223
Study 19620162 — intervention group
Group type: EXPERIMENTAL
Intervention: First examination with high-risk findings
Number of subjects: 564
Study 19620162 — intervention group
Group type: EXPERIMENTAL
Intervention: First examination with low-risk findings
Number of subjects: 564
Study 19620162 — intervention group
Group type: EXPERIMENTAL
Intervention: Second examination with high-risk findings
Number of subjects: 564
Study 19620162 — intervention group
Group type: EXPERIMENTAL
Intervention: Second examination with no adenomas
Number of subjects: 564
Study 16430412 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal ketamine (0.25 mg.kg(‐1)) plus lidocaine (2%, 2 mg.kg(‐1))
Number of subjects: 62
Study 16430412 — intervention group
Group type: COMPARATOR
Intervention: Caudal ketamine (0.25 mg.kg(‐1)) plus tramadol (1 mg.kg(‐1))
Number of subjects: 62
Study 12830445 — intervention group
Group type: EXPERIMENTAL
Intervention: Short daily hemodialysis (n = 11)
Number of subjects: 45
Study 12830445 — intervention group
Group type: EXPERIMENTAL
Intervention: Long nocturnal hemodialysis (n = 12)
Number of subjects: 45
Study 12830445 — intervention group
Group type: COMPARATOR
Intervention: Conventional thrice-weekly hemodialysis (n = 22)
Number of subjects: 45
Study 10857518 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (three series of 15 contractions against an expiratory resistance at 60% maximum expiratory pressure [PEmax] two times a day)
Number of subjects: 18
Study 10857518 — intervention group
Group type: COMPARATOR
Intervention: Control group performed breathing exercises to enhance maximal inspirations
Number of subjects: 18
Study 10857518 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Number of subjects: 18
Study 10857518 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle weakness (part 1)
Number of subjects: 18
Study 9337184 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5000 U bolus followed by 1000 to 1200 U/h)
Number of subjects: 412